Article information
Full text is only aviable in PDF
References
[1]
M.A. Pfaller, D.J. Diekema.
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem.
J Clin Microbiol Rev, 20 (2007), pp. 133-163
[2]
G.S. Martin, D.M. Mannino, S. Eaton, et al.
The epidemiology of sepsis in the United States from 1979 through 2000.
N Engl J Med, 348 (2003), pp. 1546-1554
[3]
W.E. Trick, S.K. Fridkin, J.R. Edwards, et al.
Secular trends of hospital Acquired Candidemia among Intensive Care Unit Patients in the United States during 1989–1999.
Clin Infect Dis, 35 (2002), pp. 627-630
[4]
P. Eggimann, J. Garbino, D. Pittet.
Epidemiology of Candida species infection in critically ill immunosuppressed patients.
The lancet Infect Dis, 3 (2003), pp. 685-702
[5]
C.M. Beck-Sague, W. Jarvis.
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980–1990.
J Infect Dis, 167 (1993), pp. 1247-1251
[6]
A.L. Colombo, T. Guimarães, L.R. Silva, et al.
Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality.
Infect Control Hosp Epidemiol, 28 (2007), pp. 570-576
[7]
J.C. Cornelius, B. Staley, H. Nguyen.
In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.
Antimicrob Agents Chemother, 49 (2006), pp. 767-769
[8]
M.C. Arendrup, K. Fuursted, B. Gahrn-Hansen, et al.
Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azoles susceptibility.
J Clin Microbiol, 50 (2005), pp. 3496-3498
[9]
V. Moudgal, T. Little, D. Boikov, et al.
Multiechinocandin- and multiazoleresistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.
Antimicrob Agents Chemother, 49 (2005), pp. 767-769
[10]
M. Krogh-Madsen, M.C. Arendrup, L. Heslet, et al.
Aphotericin B and Caspofungin resistence in Candida glabrata isolates recovered from a critically ill patient.
Clin Infect Dis, 42 (2006), pp. 938-944
[11]
A. Borst, M.T. Raimer, D.W. Warnock, et al.
Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.
Antimicrob Agents Chemother, 49 (2005), pp. 783-787
[12]
S.S. Magill, C. Shields, C.L. Sears, et al.
Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.
J Clin Microbiol, 44 (2006), pp. 529-535
[13]
CLSI 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. NCCLS document M27–A3. NCCLS, Wayne, PA.
[14]
B.D. Alexander, T.C. Byrne, K.L. Smith, et al.
Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.
J Clin Microbiol, 45 (2007), pp. 698-706
[15]
E. Chryssanthou.
Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre Yeast One colorimetric antifungal panel with the NCCLS M27-A reference method.
J Clin Microbiol, 39 (2001), pp. 4181-4183
[16]
E. Catón, J. Pemán, A. Valentin, et al.
Evaluation and utility of the Etest and NeoSensitabs methods in studding fluconazole yeast susceptibility.
Rev Esp Quimioterap, 19 (2006), pp. 267-274
[17]
G. Morace, G. Amato, F. Bistoni, et al.
Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards M27-A2 broth microdilution method for fluconazole susceptibility testing of Candida species.
J Clin Microbiol, 40 (2002), pp. 2953-2958
[18]
H.C. Chang, J.J. Chang, S.H. Chan, et al.
Evaluation of Etest for direct antifungal susceptibility testing of yeasts in positive blood cultures.
J Clin Microbiol, 39 (2001), pp. 1328-1333
[19]
A.L. Barry, M.A. Pfaller, R.P. Rennie, et al.
Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods.
Antimicrob Agents Chemother, 46 (2002), pp. 1781-17814
[20]
J.D. Diekema, A.S. Messer, R.J. Hollins, et al.
Evalution of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole.
J Clin Microbiol, 45 (2007), pp. 1974-1977
[21]
M.H. Nguyen, C.J. Clancy, V.L. Yu.
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.
J Infect Dis, 177 (1998), pp. 425-430
[22]
A.L. Colombo, M. Nucci, B.J. Park, et al.
Brazilian Network Candidemia Study. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers.
J Clin Microbiol, 44 (2006), pp. 2816-2823
[23]
A.M. Tortorano, A. Peman, L. Bernhardt, et al.
Epidemiology of Candidaemia in Europe: results of 28 month European Confederation of Medical Mycology (ECMM) Hospital based surveillance study.
Eur Clin Microbiol Infect Dis, 23 (2004), pp. 317-322
[24]
H. Richet, P. Roux, C. Des Champs, et al.
French Candidemia Study Group. Candidemia in French hospitals: incidence rates and characteristics.
Clin Microbiol Infec Dis, 8 (2002), pp. 405-412
[25]
M. Cuenca-Estrella, B. Almirante, D. Rodríguez.
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003.
J Clin Microbiol, 43 (2005), pp. 1829-1835
[26]
J. Pemán, E. Catón, M. Gobernado, et al.
Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 1-year multicentre study in Spain.
Eur J Clin Microbiol Infec Dis, 24 (2005), pp. 23-30
[27]
G.L. Macphail, G.D. Taylor, M. Buchanan-Chell, et al.
Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals.
Mycoses, 45 (2002), pp. 141-145
[28]
V.R. Aquino, L.W. Lunardi, L.Z. Goldani, et al.
Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil.
Braz J Infect Dis, 9 (2005), pp. 411-418
[29]
P. Godoy, I.N. Tiraboschi, L.C. Severo, et al.
Species distribution and antifungal susceptibility profile of Candida spp. Blood stream isolates from Latin American hospitals.
Mem Inst Oswaldo Cruz, 98 (2003), pp. 401-405
[30]
V. Krcmeryb, A.J. Barnes.
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
J of Hosp Infec, 50 (2002), pp. 243-260
[31]
L.R. Brito, T. Guimarães, M. Nucci.
Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals.
Med Mycol, 44 (2006), pp. 261-266
[32]
A.S. Levin, S.F. Costa, N.S. Mussi.
Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers.
Diagn Microbiol Infect Dis, 30 (1998), pp. 243-249
[33]
M. Bassetti, E. Righi, A. Costa, et al.
Epidemiological trends in nosocomial candidemia in intensive care.
BMC Infect Dis, 6 (2006), pp. 1-6
[34]
E. Girão, A.S. Levim, M. Basso, et al.
Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital.
Med Mycol, 46 (2008), pp. 581-588
[35]
A.C. Pasqualotto, R. Zimerman, V.R. Aquino, et al.
Take control over your fluconazole prescription: The growing importance of Candida glabrata as an agent of candidemia in Brazil.
Infect Control Hosp Epidemiol, 29 (2008), pp. 898-899
[36]
M.A. Pfaller, L. Boyken, R.J. Hollis, et al.
In vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance.
J Clin Microbiol, 46 (2008), pp. 150-156
[37]
M.A. Pfaller, M.G. Diekema, L. Ostrosky-Zeichner, et al.
Correlation of MIC with outcome for Candida species tested against Caspofungin, Anidulafungin: analysis and propsal for interpretative MIC breakpoints.
J Clin Microbiol 2008, 46 (2008), pp. 2620-2629
[38]
G. Effron-Garcia, S.K. Katiyar, S. Park, et al.
A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility.
Antimicrob Agents Chemother, 52 (2008), pp. 2305-2312
[39]
M.A. Pfaller, D.J. Diekema, R.N. Jones, et al.
Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997–1998.
Antimicrob Agents Chemother, 44 (2000), pp. 747-751
[40]
M.A. Pfaller, M.G. Diekema, D.L. Gibbs, et al.
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK antifungal surveillance program 2001 to 2005.
J Clin Microbiol, 46 (2008), pp. 842-849
[41]
M.A. Pfaller, M.G. Diekema, R.N. Jones, et al.
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, voriconazole and voriconazole of isolates collected from 1997 through 1999 in SENTRY antimicrobial surveillance program.
J Clin Microbiol, 39 (2001), pp. 3254-3259
[42]
M.A. Pfaller, M.G. Diekema, M.G. Rinaldi, et al.
Results from the ARTEMIS DISK global antifungal surveillance study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.
J Clin Microbiol, 43 (2005), pp. 5848-5859
[43]
L. Ostrosky-Zeichner, J.H. Rex, P.G. Pappas, et al.
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.
Antimicrob Agents Chemother, 47 (2003), pp. 3149-3154
[44]
M.A. Pfaller, S.A. Messer, L. Boyken, et al.
Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program.
J Clin Microbiol, 46 (2008), pp. 551-559
[45]
A. Epinel-Ingroff, F. Barchiesi, M. Cuenca-Estrella.
Comparison of visual 24 hour and spectrophotometric 48 hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole and voriconazole for Candida spp., a collaborative study.
J Clin Microbiol, 43 (2008), pp. 4535-4540
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved
